Search

Your search keyword '"Goadsby, Peter J"' showing total 3,019 results
Start Over Author "Goadsby, Peter J"
3,019 results on '"Goadsby, Peter J"'

23. Migraine

Author

Goadsby, Peter J., Pfaff, Donald W., editor, Volkow, Nora D., editor, and Rubenstein, John L., editor

Published
2022
Full Text
View/download PDF

27. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2–4 Prior Preventive Treatments Had Failed

Author

Reuter, Uwe, primary, Goadsby, Peter J., additional, Ferrari, Michel D., additional, Da Silva Lima, Gabriel Paiva, additional, Mondal, Subhayan, additional, Kalim, Jawed, additional, Hasan, Fatima, additional, Wen, Shihua, additional, Arkuszewski, Michal, additional, Pandhi, Shaloo, additional, Stites, Tracy, additional, and Lanteri-Minet, Michel, additional

Published
2024
Full Text
View/download PDF

35. Migraine

Author

Ferrari, Michel D., Goadsby, Peter J., Burstein, Rami, Kurth, Tobias, Ayata, Cenk, Charles, Andrew, Ashina, Messoud, van den Maagdenberg, Arn M. J. M., and Dodick, David W.

Published
2022
Full Text
View/download PDF

38. Pituitary cyclase‐activating polypeptide targeted treatments for the treatment of primary headache disorders.

Author

Karsan, Nazia, Edvinsson, Lars, Vecsei, Laszlo, and Goadsby, Peter J

Subjects
PRIMARY headache disorders, PITUITARY adenylate cyclase activating polypeptide, CALCITONIN gene-related peptide, CYCLIC adenylic acid, VASOACTIVE intestinal peptide
Abstract

Objective: Migraine is a complex and disabling neurological disorder. Recent years have witnessed the development and emergence of novel treatments for the condition, namely those targeting calcitonin gene‐related peptide (CGRP). However, there remains a substantial need for further treatments for those unresponsive to current therapies. Targeting pituitary adenylate cyclase‐activating polypeptide (PACAP) as a possible therapeutic strategy in the primary headache disorders has gained interest over recent years. Methods: This review will summarize what we know about PACAP to date: its expression, receptors, roles in migraine and cluster headache biology, insights gained from preclinical and clinical models of migraine, and therapeutic scope. Results: PACAP shares homology with vasoactive intestinal polypeptide (VIP) and is one of several vasoactive neuropeptides along with CGRP and VIP, which has been implicated in migraine neurobiology. PACAP is widely expressed in areas of interest in migraine pathophysiology, such as the thalamus, trigeminal nucleus caudalis, and sphenopalatine ganglion. Preclinical evidence suggests a role for PACAP in trigeminovascular sensitization, while clinical evidence shows ictal release of PACAP in migraine and intravenous infusion of PACAP triggering attacks in susceptible individuals. PACAP leads to dural vasodilatation and secondary central phenomena via its binding to different G‐protein‐coupled receptors, and intracellular downstream effects through cyclic adenosine monophosphate (cAMP) and phosphokinase C (PKC). Targeting PACAP as a therapeutic strategy in headache has been explored using monoclonal antibodies developed against PACAP and against the PAC1 receptor, with initial positive results. Interpretation: Future clinical trials hold considerable promise for a new therapeutic approach using PACAP‐targeted therapies in both migraine and cluster headache. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

39. Migraine

Author

Ajona, David Moreno, primary, Martínez, María Dolores Villar, additional, Chan, Calvin, additional, and Goadsby, Peter J., additional

Published
2022
Full Text
View/download PDF

48. Occipital headaches and neuroimaging in children

Author

Bear, Joshua J, Gelfand, Amy A, Goadsby, Peter J, and Bass, Nancy

Subjects
Chronic Pain, Clinical Trials and Supportive Activities, Neurosciences, Clinical Research, Pediatric, Dental/Oral and Craniofacial Disease, Headaches, Pain Research, Neurological, Adolescent, Child, Child, Preschool, Female, Follow-Up Studies, Headache, Humans, Male, Migraine Disorders, Neuroimaging, Occipital Lobe, Retrospective Studies, Clinical Sciences, Cognitive Sciences, Neurology & Neurosurgery
Abstract

ObjectiveTo investigate the common thinking, as reinforced by the International Classification of Headache Disorders, 3rd edition (beta), that occipital headaches in children are rare and suggestive of serious intracranial pathology.MethodsWe performed a retrospective chart review cohort study of all patients ≤18 years of age referred to a university child neurology clinic for headache in 2009. Patients were stratified by headache location: solely occipital, occipital plus other area(s) of head pain, or no occipital involvement. Children with abnormal neurologic examinations were excluded. We assessed location as a predictor of whether neuroimaging was ordered and whether intracranial pathology was found. Analyses were performed with cohort study tools in Stata/SE 13.0 (StataCorp, College Station, TX).ResultsA total of 308 patients were included. Median age was 12 years (32 months-18 years), and 57% were female. Headaches were solely occipital in 7% and occipital-plus in 14%. Patients with occipital head pain were more likely to undergo neuroimaging than those without occipital involvement (solely occipital: 95%, relative risk [RR] 10.5, 95% confidence interval [CI] 1.4-77.3; occipital-plus: 88%, RR 3.7, 95% CI 1.5-9.2; no occipital pain: 63%, referent). Occipital pain alone or with other locations was not significantly associated with radiographic evidence of clinically significant intracranial pathology.ConclusionsChildren with occipital headache are more likely to undergo neuroimaging. In the absence of concerning features on the history and in the setting of a normal neurologic examination, neuroimaging can be deferred in most pediatric patients when occipital pain is present.

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results